Dividend stocks alert, record date: Last chance to buy - Blue Dart, Karnataka Bank, Aarti Pharma, ITDC | Full list
NiveshIQ
NSE: AARTIPHARM · Pharma
Aarti Pharmalabs Ltd.
₹826.95▲ ₹1.20 (+0.15%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on AARTIPHARM. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Aarti Pharmalabs Ltd.
Aarti Pharmalabs Limited (AARTIPHARM) is a diversified Indian pharmaceutical manufacturer that produces active pharmaceutical ingredients (APIs), intermediates, and xanthine derivatives for both domestic and international markets. The company’s API portfolio spans cardiovascular, anti‑asthmatic, anti‑cancer, anti‑diabetic, CNS, and ophthalmic segments, while its contract development and manufacturing services cater to drug‑substance projects. In FY 2025‑26, Aarti Pharmalabs reported revenue of ₹1,969 cr and net income of ₹205 cr, reflecting a solid earnings base. Recent developments include a ₹59.5 cr stamp‑duty penalty related to a demerger, and the company has announced a target of 15‑18 % revenue and EBITDA growth over the next 3‑4 years. Competitively, the firm leverages its broad API
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,853 Cr -4.70% | ₹2,115 Cr +14.10% | ₹1,819 Cr -14.00% |
| EBITDA Margin | 20.83% | 22.43% | 20.83% |
| Net Profit | ₹217.00 Cr +12.40% | ₹272.40 Cr +25.50% | ₹169.50 Cr -37.80% |
| EPS | ₹23.93 | ₹30.05 | ₹19.27 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Aarti PharmaLabs Publishes Saksham Niveshak Campaign Advertisements Under Regulation 30
Aarti Pharmalabs: Can New Capacity Turn Growth into Returns?
🔒
+ 3 more stories about Aarti Pharmalabs Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹536 Cr, PAT ₹76 Cr, EPS ₹8.40, EBITDA margin 25.5%. Growth context: revenue QoQ -8.0%, PAT QoQ +24.6%.
Management highlights R&D investments and technology initiatives as the primary near‑term growth lever, with execution o...
FY26 (last completed FY): revenue ₹1, 819 Cr, PAT ₹170 Cr, EBITDA margin 20.8%, EPS ₹19.27. Year-on-year: revenue YoY -1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for AARTIPHARM
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track AARTIPHARM alongside your other holdings
Unlock full AARTIPHARM research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Aarti Pharmalabs Ltd.?
NiveshIQ detects active intelligence signals for Aarti Pharmalabs Ltd. (AARTIPHARM) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Aarti Pharmalabs Ltd.?
Aarti Pharmalabs Ltd. operates in the Pharma sector with a market capitalisation of ₹619,297.8L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.